FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

 
• By Alaric DeArment
FibroGen said 5 May that the Phase III study of roxadustat in MDS did not meet its primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D